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Abstract
The proliferation and differentiation of normal prostate epithelial cells depends upon the action of
androgens produced by the testis. Prostate cancers retain the ability to respond to androgens in the
initial stages of cancer development, but progressively become independent of exogenous androgens
in advanced stages of the disease while maintaining the expression of functional androgen receptor
(AR). In the present study, we have determined the potential of prostate cancer cells to synthesize
androgens from cholesterol which may be involved in intracrine regulation of AR in advanced stages
of the disease Established androgen- independent prostate cancer cell lines, PC3 and DU145 cells,
expressed mRNA and proteins for scavenger receptor type B1 (SRB1), steroidogenic acute regulatory
(StAR) protein, cytochrome P450 cholesterol side chain cleavage (P450scc), 3 -hydroxysteroid
dehydrogenase (3 -HSD) and other enzymes involved in androgen biosynthesis. Expression of all
these proteins and enzymes was significantly higher in the androgen-independent derivative of
LNCaP prostate cancer cells (C81) than in the androgen-dependent cell line (C33). In serum-free
cultures, the androgen-independent C81 cells secreted ~5 fold higher testosterone than C33 cells as
determined in the conditioned media by immunoassays. These cells could also directly convert
radioactive cholesterol into testosterone which was identified by thin layer chromatography. These
results for the first time show that prostate cancer cells in advanced stages of the disease could
synthesize androgens from cholesterol and hence are not dependent upon testicular and/or adrenal
androgens.
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Prostate cancer is the most frequently diagnosed malignancy in men and the second leading
cause of male cancer related deaths in the United States (Jemal, et. al., 2005). The majority of
prostate cancers are dependent upon androgens at initial diagnosis, and endocrine therapy is
directed toward removal of androgen source (castration) or inhibition of androgen synthesis in
the testicular Leydig cells (Griffiths, et. al., 1997). However, there is a progressive loss of
androgen dependency (castration-resistance) during advanced stages of prostate cancer and the
tumor cells do not respond to hormonal treatments (Feldman and Feldman, 2001) indicating
that these cells acquire the potential to survive and proliferate in the absence of exogenous
testosterone (Chen, et. al., 2004).
Studies using archival patient samples have shown increased expression of androgen receptor
(AR) in advanced stages of prostate cancer and/or that AR becomes supersensitive to androgens
and antiandrogens (Chen, et. al., 2004,Gelmann, 2002,Mohler, et. al., 2004); a two to five fold
increase in AR mRNA is the only gene expression change consistently associated with hormone
refractory disease (Chen, et. al., 2004). Immunohistochemical localization studies show that
AR is present in primary site and metastatic prostate cancers regardless of stage and grade, as
well as in hormone refractory cancers (Mostaghel, et. al., 2007). These findings are supported
by in vitro data showing that inhibition of AR expression in hormone refractory prostate cancer
cells results in inhibition of growth and survival, indicating an essential role of AR in advanced
stages of prostate cancer (Chen, et. al., 2004). These in vivo and in vitro studies suggest that
some unknown factor(s) produced in prostate cancer cells is able to activate and maintain the
function of AR (Gelmann, 2002). It has been recently shown that the levels of testosterone,
DHT and androgen precursors in the prostate tissue of patients with recurrent prostate cancers
following medical or surgical castration, are present at levels sufficient for AR activation
(Mohler, et. al., 2004,Titus, et. al., 2005).
The possibility that the prostate cancer cells may acquire steroidogenic potential and may
produce androgens which bind to AR and stimulate gene expression has also been explored
(Ellem, et. al., 2004,Holzbeierlein, et. al., 2004). Several studies have indicated that other
steroidal ligands such as estradiol may be able to activate AR (Kaplan, 1969). The AR in these
cells may be mutated causing hypersensitivity of the receptor and the promiscuous usage of
other steroid ligands such as cortisol, estrogen, and progesterone (Gelmann, 2002). Expression
of aromatase which converts androgens to estrogens, is also altered in prostate cancer cells
(Ellem and Risbridger, 2006). Therefore, it has been postulated that prostate cancer cells are
capable of converting steroid precursors into androgens and estrogens which serve as ligands
for their respective receptors (El-Alfy, et. al., 1999,Nakamura, et. al., 2005). The central
hypothesis in the previous studies have focused on either the role of low (castration) levels of
serum androgens or androgens synthesized from adrenal precursors as potential regulators of
AR in hormone refractory advanced prostate cancers. However, the possibility that prostate
cancer cells acquire complete steroidogenic potential to synthesize androgens from cholesterol
has not been explored, although upregulation of genes involved in cholesterol biosynthesis
from acetate in androgen independent prostate cancers has been reported (Holzbeierlein, et.
al., 2004,Stanbrough, et. al., 2006);. In this study we demonstrate for the first time the
expression of cellular proteins involved in key steps in steroidogenesis in the prostate cancer
model cell lines and show that prostate cancer cells are capable of producing testosterone
directly from cholesterol.
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Cell lines and cell culture
Human prostate cancer cell lines DU145 and PC3 were purchased from American Type Cell
Culture Collection (Rockville, MD). Clonetics® normal human prostate epithelial cells (PrEC)
were purchased from Lonza (Allendale, NJ). For these experiments, LNCaP prostate cancer
cell progression model (Igawa, et. al., 2002) includes cells that have passage numbers less than
33 are designated as clone 33 (C33) and the passage numbers over 80 as clone 81 (C81). These
cell lines recapitulate the phenomenon of clinical tumor progression and C81 cells express PSA
in the absence of exogenous androgens (Igawa, et. al., 2002). DU145 and PC3 cells were
cultured in Eagle's minimum essential medium with Earle's salts and amino acid supplements
(Millena, et. al., 2004). LNCaP -C33, and –C81 cells were routinely maintained in RPMI 1640
(Igawa, et. al., 2002) containing 10% fetal bovine serum (HyClone, South Logan, Utah). PrEC
cells were cultured in Prostate Epithelial Cell Basal Medium according to the supplier’s
instructions. RNA and total proteins from H295R adrenal carcinoma and JEG3
choriocarcinoma cells were provided by Dr. Marion Sewer (Georgia Institute of Technology,
Atlanta) and were used as positive controls for steroidogenic proteins and enzymes.
RNA isolation, cDNA synthesis and RT-PCR
For RT-PCR analysis, cells were cultured in 6-well plates overnight in the presence of 10%
FBS. After 24h, cells were washed with 1× PBS, and cultured in serum-free media for 48 h.
Total RNA was isolated from the cells using TRIzol (Invitrogen, Carlsbad, CA) and quantified
by optical density reading at 260 nm as described earlier (Millena, et. al., 2004). PCR reactions
were performed using MasterCycler gradient (Eppendorf AG, Hamburg, Germany) using the
procedures described previously (Millena, et. al., 2004). For PCR, 2 µl of cDNA were added
to separate PCR reaction mixtures (total 10 µl) containing 0.1 mM dNTPs, (Promega, Madison,
WI), 0.5 U Taq DNA polymerase (PGC Scientifics, Frederick, MD), 1× standard PCR buffer
with 1.5 mM MgCl2 and 25 pmol of gene-specific primers. Cycling conditions for the
MasterCycler were 94°C for 2 min (initial denaturation), 94°C for 1 min, 60°C or 62°C for 1
min, 72°C for 2 min for 30–35 cycles, and 72°C for 5 min (final extension). L19 (a ribosomal
protein) primer pair was used as an internal control. The oligonucleotide pair for L19 was
synthesized according to previously published report (Millena, et. al., 2004). All other gene-
specific primers were designed using Beacon Designer 5.0 (Premier Biosoft International, Palo
Alto, CA) software program. Sequences of all primers used in RT-PCR experiments are shown
in Table 1. The PCR products were visualized on 1.5% agarose gels stained with ethidium
bromide. Relative amounts of PCR products were estimated by digital densitometry (GE-
Amersham, Piscataway, NJ). Density values for each gene-specific PCR band was normalized
with L19 bands. The PCR products were sequenced to confirm the identities of the specific
mRNAs. Three independent experiments were performed and the data analyzed using student
t-test and ANOVA. Representative RT-PCR results are shown in the figures.
Western blot analyses
The antibodies against StAR, P450scc and Cyp 17 were obtained from Dr. Buck Hales
(University of Illinois, Chicago). Cells were cultured in 10 cm2 dishes to 70% confluency,
washed twice with PBS and lysed in cell lysis buffer (Cell Signaling Technology, Beverly,
MA) and the protein concentrations were determined as described previously (Millena, et. al.,
2004). Cell lysates were mixed with Laemmli’s buffer (62.5 mM Tris, pH 6.8, 2% SDS, 5%
-mercaptoethanol and 10% glycerol) and individual samples (30 µg protein) were subjected
to SDS-PAGE in 10% gels and transferred to PVDF membranes (Millipore, Bedford, MA).
Western blot analyses were performed by the procedures described previously (Millena, et. al.,
2004). The membranes were incubated with appropriate dilutions of specific primary
antibodies (over night at 4° C) and with secondary antibodies (anti-rabbit or anti-mouse
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immunoglobulin coupled to horseradish peroxidase) at appropriate dilutions for 1h at room
temperature. Western blots for -actin were carried out in parallel as loading controls. The
relative intensities of specific protein bands were determined by densitometric analysis of
images using ImageQuant software (GE-Amersham).
Radioimmunassay of testosterone
LNCaP- C33, -C81, DU145 and PC3 cells were plated in 6-well plates and cultured in serum
free medium for 48 hours, after which conditioned media were collected and analyzed for total
androgens using a radioimmunoassay (Millena, et. al., 2004). The antiserum employed in this
immunoassay exhibits 77 and 26% cross-reactivity to 5 -dihydrotestosterone and 5  -
androstane, 3 , 17  diol, respectively and hence is ideal for determination of total androgens
(Ismail, et. al., 1972).
Thin layer chromatography (TLC)
LNCaP-C33, -C81, DU145, and PC3 cells were plated in six well plates (106 cells/well), treated
with 3H-Cholesterol (1 µCi, 34 µM) in 1 ml of serum-free medium and incubated for 48 hours.
The cells and media were extracted twice with chloroform/acetone (1:1, v/v) (Schmidt, et. al.,
2005). The combined extracts were dried at 76°C, subjected to TLC on silica gel G plates and
developed with chloroform/diethylether (1:1, v/v) (Schmidt, et. al., 2005).Purified unlabeled
cholesterol and testosterone standards were either added to the cell extracts or ran in parallel
on the TLC plates. For identification of spots the silica gel plates were stained using
phosphomolybdic acid then dried with a heat gun (Schmidt, et. al., 2005). Blue-black spots
were visualized identifying the locations of the testosterone and cholesterol standards. Spots
were excised, added to liquid scintillation fluid and radioactivity was determined using a
scintillation counter (Schmidt, et. al., 2005).
Results and Discussion
The results described in this study show for the first time that androgen-independent human
prostate cancer cells are able to acquire complete steroidogenic potential and are capable of
synthesizing testosterone from cholesterol, indicating an intracrine regulation of AR in
advanced stages of prostate cancer. Several studies have shown the expression of key
steroidogenic enzymes in prostate cancer cells indicating that these cells are able to synthesize
androgens from adrenal precursors (El-Alfy, et. al., 1999,Nakamura, et. al., 2005,Stanbrough,
et. al., 2006). The presence of functional AR in advanced stages of the disease and the presence
of testosterone and DHT, sufficient to activate the AR, in cancer tissues under androgen
ablation therapy, also support this notion (Gelmann, 2002,Mohler, et. al., 2004,Titus, et. al.,
2005). The purpose of our studies was to determine whether prostate cancer cells in advanced
stages of the disease can synthesize testosterone from cholesterol hence making them
completely independent of serum testosterone and/or adrenal steroid precursors.
Figure 1 shows the key components of steroidogenic machinery required for cholesterol uptake
(SRB-1), cholesterol transport into inner mitochondrial membrane (StAR protein) and enzymes
required to convert cholesterol into pregnenolone (P450scc) and subsequently into testosterone
(Stocco, 2001). As a first step we determined the expression of SRB-1, StAR, P450scc,
3 HSD, CYP17 and 17 HSD1 in normal prostate epithelial cells (PrEC) and two established
androgen-independent prostate cancer cell lines (DU145 and PC3), along with human adrenal
carcinoma (H295R) and choriocarcinoma (JEG3) cell lines (Figure 2). RT-PCR analyses
revealed very low or undetectable expression of StAR, P450scc and CYP17 in PrEC cells.
However, expression of all components of steroidogenesis was detected in both DU145 and
PC3 cells. The expression of StAR was detected at a low level in these cells compared to H295R
cells. The placental cells (JEG3) are known not to express StAR protein and to use other
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members of this protein family to transport cholesterol into mitochondria (Watari, et. al.,
1997). All cell lines including PrEC cells expressed comparable levels of 17 -HSD1 which
was confirmed by sequencing the PCR-product. Previous studies have identified different
isoforms of 17  -HSD in several tissues have shown that while 17  -HSD1 and 17  -HSD5
are present in prostate cancer cells, 17 - HSD3 is primarily expressed in the testis (Labrie, et.
al., 1997). Previous studies have shown the presence of 17  -HSD1 in the prostate, and in
LNCaP cells using RNAse protection assays (Labrie, et. al., 1997). However, another study
failed to detect 17 - HSD1 in prostate cancer cell lines (LNCap, DU145, PC3) using northern
blotting (Castagnetta, et. al., 1997). The reasons for this discrepancy could be due to the
differential sensitivity of methods employed by the two studies.
To determine whether the expression of steroidogenic machinery correlates with independence
from exogenous testosterone, we employed cell lines derived from LNCaP cells, which
represent this phenomenon in vitro. C33 and C81 cells are both AR positive, however C33
cells are androgen dependent and C81 cells do not require exogenous androgens for survival
and proliferation (Igawa, et. al., 2002). These cell lines recapitulate the phenomenon of clinical
tumor progression and have been validated and used as models of androgen-independent cells
in subsequent studies from different laboratories (Cai, et. al., 2007,Cao, et. al., 2006,Denmeade,
et. al., 2003,Unni, et. al., 2004). PSA secretion by C81 cells in the absence of androgens is
much higher than that secreted by C33 cells which is a biomarker for androgen-independence
and is seen in other in vitro models of androgen independent prostate cancers (Chen, et. al.,
2007,Hara, et. al., 2003). Data presented in Figure 3A confirmed the presence of AR mRNA
and protein in C33 and C81 cells (Igawa, et. al., 2002) and showed no expression of AR in
PC3 and DU145 cells. The presence of functional AR makes C33 and C81 cells a better model
for these studies. We determined the expression of all steroidogenic enzymes and proteins in
C33 and C81cells by RT-PCR as described above. The results of these determinations are
presented in Figure 3B. All key components of steroidogenic machinery are expressed in
androgen-independent C81 cells. Both C33 and C81 cells expressed SRB1, P450scc, 3  HSD
and 17 HSD1 at comparable levels; however StAR expression was low in C33 cells compared
to C81 cells and no expression of CYP17 was detected in C33 cells. The steady state mRNA
levels for StAR and P450scc in C81 cells were 4.7-fold and 1.3-fold higher than those in C33
cells, respectively. Similar differences in the expression of StAR mRNA were observed using
real time PCR analysis (data not shown). These results were confirmed using Western blot
analysis as shown in Figure 3C. StAR protein was not detected in PrEC cells and is present at
low levels in C33 cells. C81 cells contained higher amount of StAR protein when compared
with C33 cells. The protein levels of StAR and P450scc in C81 cells were 2.6-fold and 1.7-
fold higher than those in C33 cells. We also detected presence of StAR protein in PC3 and
DU145 cells. Our results also showed that CYP17 is not expressed either at mRNA or at protein
level in PrEC and C33 cells; however, significant expression of CYP17 mRNA and protein
were present in C81 cells. Since StAR is critical for cholesterol transport into mitochondria
and CYP17 is required for androgen synthesis from progesterone, C33 cells may have very
low or limited capacity to synthesize androgen from cholesterol (Stocco, 2001).
These data suggest that androgen independence in prostate cancer cell lines correlates with the
acquisition of proteins required for androgen biosynthesis from cholesterol. To determine
whether these cells synthesize androgens in vitro, the cells were cultured for 48 hr in serum-
free media and androgen levels were determined in conditioned media using RIA. As shown
in Figure 4A, detectable levels of androgens were present in the conditioned media from both
C33 and C81 cells cultured in the absence of serum. Nevertheless, C81 cells secreted
approximately five-fold higher androgens than C33 cells. Levels of androgens in the
conditioned media from PC3 and DU145 cells and also in unrelated control cells or in the
culture medium without the cells were undetectable (HeLa, COS; data not shown). These data
show that androgen independence is indeed associated with androgen secretion by C81 cells
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in the absence of exogenous steroid precursors. The reason for undetectable levels of
testosterone in conditioned media from PC3 and DU145 cells could be due to a) low production
of testosterone by these cells as a consequence of low expression of StAR, or b) due to its
conversion to estradiol by aromatase. The second possibility is supported by high levels of
aromatase in these cell lines (Dillard et al, unpublished data;(Ellem and Risbridger, 2006);
androgens may be irrelevant in these cell lines since they do not express AR.
To confirm that the C33 and C81 cells are capable of using cholesterol uptake and its conversion
into androgens, we determined the conversion of labeled exogenous cholesterol to testosterone
in these cells. The cells were cultured in the presence of 1 , 2  [N] - 3H-cholesterol for 48 hr
in serum-free medium. The conditioned media and cell extracts were then analyzed for the
presence of labeled testosterone by TLC. Figure 4B shows the separation of testosterone and
cholesterol by TLC (upper panel). The spots representing cholesterol and testosterone were
scraped and counted in the scintillation counter. The results showed conversion of radiolabeled
cholesterol into tesotosterone by both cell lines. The radioactivity observed in C33 cells was
3613 ± 1004 cpm and 191±45 cpm (Mean±SEM; n=3) for cholesterol and testosterone spots,
respectively. The corresponding radioactive in C81 cells was 3268±1309 and 225±45, for
cholesterol and testosterone, respectively. The differences in the levels of radioactive
testosterone were not statistically significant and were different than those observed for RIA.
The reason for this discrepancy were probably due to the fact that RIA determines the levels
of all androgens while only testosterone spots were analyzed in the TLC. Any conversion of
testosterone into DHT or other metabolites may account for these differences. In addition,
while only conditioned media were analyzed in the RIA, both cell extracts and media were
combined for TLC analysis. Nevertheless, it should also be noted that DHT is more active form
of androgens than T in prostate cells. Additional studies involving separation of all androgenic
steroids and analysis will be required to clarify this point. However, the fact that we did find
radioactive testosterone in these cells and since radioactive testosterone could only be
synthesized from radioactive cholesterol, this experiment conclusively demonstrated that these
cells are capable of making androgens directly from exogenous cholesterol. The specificity of
this conversion was also supported by the fact that we did not detect any radioactive testosterone
in DU145 and PC3 cells (data not shown) confirming our RIA results.
Mohler and collaborators (Mohler, et. al., 2004,Titus, et. al., 2005) reported the presence of
significant amounts of testosterone and DHT in the recurrent prostate cancer tissues and
suggested that prostate cancer cells may synthesize androgens from adrenal precursors or
cholesterol (El-Alfy, et. al., 1999,Nakamura, et. al., 2005,Stanbrough, et. al., 2006). Our studies
support the notion that this testosterone can be synthesized directly from cholesterol. This
possibility is also supported by the fact that genes regulating cholesterol biosynthesis are
upregulated in androgen ablation resistant prostate cancer cells (Holzbeierlein, et. al., 2004)
suggesting that prostate cancer cells may also be able to increase biosynthesis of intracellular
cholesterol.
In conclusion, our results clearly show for the first time that advanced androgen independent
prostate cancer cells acquire complete steroidogenic ability to synthesize androgens and
underline the fact that castration and inhibition of testosterone production in the testes may not
achieve androgen deficiency in prostate cancer cells in advanced stages of the disease. Our
results also explain the essential role of AR in survival and proliferation of androgen-
independent prostate cancers under androgen-ablation therapy and suggest that inhibitors of
steroid biosynthesis in prostate cancer cells may be required to completely abolish the
androgens in these tumors for its therapy.
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Diagram illustrating pathways involved in biosynthesis and metabolism of testosterone.
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RT-PCR analysis of mRNAs fro steroidogenic enzymes and other proteins required for
androgen biosynthesis in normal prostate epithelial cells (PrEC; 2A) and androgen independent
prostate cancer cell lines (PC3 and DU 145; 2B). Established steroidogenic cell lines (H295R
and JEG3) served as positive controls.
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Expression of AR and steroidogenic machinery in prostate cancer cells
A. RT-PCR (upper panel) and Western blot (lower panel) analysis of AR mRNA and protein
in C33 (androgen dependent), C81 (androgen independent), and AR negative DU145, and PC3
prostate cancer cell lines. Ribosomal L19 and -actin were used as controls in RT-PCR and
Western blots, respectively.
B. RT-PCR analysis of steroidogenic enzymes and other proteins required for androgen
biosynthesis in C33 and C81prostate carcinoma cells.
C. Western blotting for StAR, P450scc (upper panel), and CYP17 (lower panel) protein in C33,
C81, DU145 and PC3, PrEC, and H295R cells.
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Androgen production in androgen dependent (C33) and androgen independent (C81) prostate
carcinoma cells
A. The cells were cultured in serum-free medium for 48 hr and the conditioned media were
collected and analyzed for androgen content by radioimmunoassay. Each bar represents Mean
± SD from triplicate determinations.
B. Thin layer chromatography (TLC) separation of testosterone and cholesterol in C33 and
C81 prostate cancer cells. The cells were cultured in serum-free medium containing 3H-
cholesterol (1µci/ml) for 48 hr and the cells and conditioned media were collected. The cells
and media were combined and extracted and the extracts were subjected to TLC. Purified
unlabeled cholesterol and testosterone standards were added to the cell extracts for
identification of spots using phosphomolybdic acid. Blue-black spots identifying the locations
of the testosterone and cholesterol standards (4B) were excised, added to liquid scintillation
fluid and radioactivity was determined using a scintillation counter. An equivalent spot from
an unrelated area of the TLC plate was used as background.
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Table 1
Primer Sequences for RT-PCR
Gene Sense Primer Antisense Primer Product Size (bp)
SRB-1 AGGCATTGGACAAACTGGGAAG TGTCATCAGGGATTCAGAATAGGC 296
StAR ACCCGTTGGCTGGAAGTC GATTCTCCTGATGAGCGTGTG 238
CYP11 CGTCATTTTTGGGGAGCGCC TGCAGGGTCATGGACGTCGT 372
3 -HSD GGGCCCAACTCCTACAAGGA ACTTGGGGCCTTCTTGGGGT 356
CYP17 AGCTCGTGGCTCTCTTGCTG CGCGATGTCTAGAGTTGCCA 307
17 -HSD GTGCTCATCACCGGCTGTTC GGCCACGGATTTTGAGTCCC 207
L19 GAAATCGCCAATGCCAACTC TCTTAGACCTGCGAGCCTCA 405
GAPDH GAAGGTGAAGGTTCGGAGTC GAAGATGGTGATGGGATTTC 200
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